Entry Detail


General Information

Database ID:exR0093269
RNA Name:hsa-miR-20a-3p
RNA Type:miRNA
Chromosome:chr13
Starnd:+
Coordinate:
Start Site(bp):91351108End Site(bp):91351129
External Links:hsa-miR-20a-3p



Disease Information

Disease Name:Benign Ovarian Disease
Disease Category:Urogenital Diseases and Pregnancy Complications
MeSH ID:D010049
Type:Diseases Category/Female Urogenital Diseases and Pregnancy Complications
Alias:Ovarian Diseases//Disease, Ovarian//Diseases, Ovarian//Ovarian Disease



Expression Detail

GEO ID:GSE106817
Description:Integrated extracellular microRNA profiling for ovarian cancer screening
Experimental Design:Cancer vs Control
Case Disease Type:Benign Ovarian Disease
Case Disease SubType:NA
Case Sample:Benign Ovarian Disease
Control Sample:Non-Cancer
Number of Case:29
Number of Control:2759
Number of Samples:2788





Regulatory Relationship

mRNA targets:
Gene SymbolChromosomeStart Site(bp)End Site(bp)Strand
STK38
chr6
36493892
36547479
-
INTS11
chr1
1311585
1324691
-
POC1A
chr3
52075226
52154690
-
SPOPL
chr2
138501770
138573547
+
miRNA targets:NA
circRNA targets:NA
lncRNA targets:NA
Display:



Experiment Detail

GEO ID:GSE106817
Sample Source:Blood
Source Fraction:Serum
Platform:GPL21263
Method:Microarray
Num of detected RNA Type:1
Num of detected RNAs of this Type:2535
Sample treatment protocol:NA
RNA Extract protocol:Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).
RNA library preparation protocol:miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.



Reference

PMID:30333487
Title:Integrated extracellular microRNA profiling for ovarian cancer screening
Author:Yokoi A, Matsuzaki J, Yamamoto Y, Yoneoka Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda SI, Sonoda T, Kawauchi J, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Kato T, Ochiya T
Journal:Nat Commun. 2018 Oct 17;9(1):4319.
Description:to develop an optimal detection method, we use microarrays to obtain comprehensive miRNA profiles from 4046 serum samples, including 428 patients with ovarian tumors.